Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ACNU/CED plus temozolomide for recurrent brainstem glioma
jRCTs021180011Phase 2Completed
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimustine and temozolomide in brainstem glioma and diffuse intrinsic pontine glioma (DIPG). Started Dec 2016; status: completed.
02
Drugs
nimustinetemozolomide
03
Conditions
brainstem gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on jRCTs021180011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180011.